Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Isehara
Clinical trial register · Japan

Clinical Trials in Isehara, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2516 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:19 UTC
2516
Studies in scope
all four open statuses
1285
Recruiting now
open to new participants
352
Lead sponsors
across recruiting studies
Top sites
Fukuoka 557 Nagoya 513 Sapporo 400 Tokyo 375 Osaka 354
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC6 Eli Lilly and Company6 Novartis Pharmaceuticals6 Janssen Research & Development, LLC4 Sanofi3 Chugai Pharmaceutical2 Bristol-Myers Squibb2 Boehringer Ingelheim2 Daiichi Sankyo2 Incyte Corporation2 AbbVie2 Takeda1 Medtronic Cardiovascular1 AstraZeneca1 Medtronic Spinal and Biologics1 Stemline Therapeutics, Inc.1 Loxo Oncology, Inc.1 NovoCure GmbH1 Pfizer1 Genmab1 OCEAN-SHD Study Group1 Colorado Prevention Center1 UCB Biopharma SRL1 Osaka University1 CellSeed Inc.1 Show all 26
Site location
Fukuoka557 Nagoya513 Sapporo400 Tokyo375 Osaka354 Chiba328 Kashiwa317 Yokohama272 Kobe239 Kyoto231 Hiroshima224 Sendai207 Chūōku202 Matsuyama172 Bunkyō City171 Kanazawa149 Kumamoto147 Okayama133 Kashiwa-shi132 Niigata120 Fukushima114 Kagoshima107 Kanagawa105 Aichi104 Gifu103 Show all 938
All 938 locations
Target enrolment
to

Trials with a site in Isehara

52 of 2516 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Daiichi Sankyo
Phase 1/2
220
Kashiwa, Isehara, Yokohama, Hirakata, Chuo-ku, Koto-ku, Shinagawa-ku, Fukuoka
2026-09-17
Recruiting
Stemline Therapeutics, Inc.
Phase 2
70
Chiba, Fukuoka, Hirakata, Hiroshima, Ina, Isehara, Kagoshima, Kōtō City
2026-08-18
Recruiting
Eli Lilly and Company
Phase 2
531
Chūōku, Fujiidera, Isehara, Kobe, Kumamoto, Sapporo, Shinjuku-Ku
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
342
Chūōku, Isehara, Kobe, Sapporo, Shinjuku-Ku
2026-04-29
Recruiting
MDT-0123 Japan Study
NCT07414745Disc Degeneration, Spinal Deformity
Medtronic Spinal and Biologics
Phase 3
140
Kobe, Isehara, Higashiosaka, Koshigaya, Hamamatsu, Adachi-Ku, Minato-Ku, Nakano-Ku
2026-04-24
Recruiting
Eli Lilly and Company
Phase 4
150
Isehara
2026-03-09
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Aichi, Bunkyō City, Chiba, Chūō, Fuchū, Fukuoka, Fukushima, Isehara
2026-03-05
Recruiting
AbbVie
Phase 2/3
680
Nagoya, Matsuyama, Kurume-shi, Isehara, Kyoto
2026-01-08
Recruiting
Sanofi
Phase 3
980
Shizuoka, Asahikawa, Bunkyō City, Chikushino-shi, Fukuoka, Hachiōji, Isehara, Isesaki
2025-10-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Nagoya, Chiba, Matsuyama, Otashi, Sapporo, Kanazawa, Isehara, Yokohama
2025-09-11
Recruiting
AbbVie
Observational
700
Maebashi, Asahikawa-shi, Sapporo, Kagoshima, Isehara, Yokohama, Kyoto, Kurashiki
2025-09-09
Recruiting
Pfizer
Phase 3
400
Chiba, Kashiwa, Matsuyama, Otashi, Isehara, Yokohama, Suita, Bunkyo-ku
2025-08-05
Recruiting
Osaka University
Not applicable
450
Matsudo, Urayasu, Kitakyushu, Kurume, Nishinomiya, Isehara, Kamakura, Kawasaki
2025-06-01
Recruiting
Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure
NCT07125417Nonvalvular Atrial Fibrillation, Aspirin, Non-Antithrombotic Therapy, High Bleeding Risk
OCEAN-SHD Study Group
Phase 4
500
Nagoya, Toyohashi, Matsudo, Kitakyushu, Gifu, Sapporo, Isehara, Kawasaki
2025-05-29
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Aichi-Ken, Cho-ku, Fukuoka, Isehara, Miyagi-Ken, Sapporo
2025-05-20
Recruiting
Eli Lilly and Company
Phase 4
279
Aichi-Ken, Cho-ku, Fukuoka, Isehara, Miyagi-Ken, Sapporo
2025-05-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Nagoya, Kashiwa, Matsuyama, Sapporo, Kahoku-gun, Isehara, Kawasaki, Sagamihara
2025-03-16
Active, closed
Sanofi
Phase 3
231
Ichikawa, Narita, Isehara, Odawara, Yokohama, Suwa, Kusatsu, Fukui
2025-02-12
Active, closed
NovoCure GmbH
Phase 3
741
Toyoake-shi, Isehara, Fukuoka, Hokkaido, Ishikawa, Kumamoto, Kyoto, Mitaka
2025-02-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Nagoya, Kashiwa, Matsuyama, Kobe, Kanazawa, Isehara, Sendai, Sakai
2025-01-27
By invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
NCT06723106Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Sapporo, Himeji, Isehara, Sendai, Kawachi-Nagano, Sakai, Suita, Hamamatsu
2024-12-09
Active, closed
Eli Lilly and Company
Phase 2
143
Chiba, Chikushino-shi, Fukuoak, Hachinohe-shi, Hirosaki, Hiroshima, Isehara, Isesaki-shi
2024-10-10
Active, closed
Boehringer Ingelheim
Phase 3
8,371
Asahikawa-Shi, Chiba, Chuo-Shi, Fukuoka, Isehara, Izumo, Kurashiki-Shi, Kurume
2024-08-30
Recruiting
Colorado Prevention Center
Phase 3
2,600
Sapporo, Isehara, Sagamihara, Kyoto, Sendai, Osaka, Suita, Ōta-ku
2024-08-20
Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Sapporo, Himeji, Isehara, Sendai, Sakai, Suita, Hamamatsu, Bunkyō-Ku
2024-08-19
Active, closed
Genmab
Phase 3
379
Toyoake, Matsuyama, Fukuoka, Fukushima, Sapporo, Amagasaki, Kagoshima, Isehara
2024-08-13
Recruiting
Boehringer Ingelheim
Phase 1/2
910
Aichi, Nagoya, Isehara, Kagoshima, Kanagawa, Yokohama, Kashiwa-shi, Kyoto, Osaka, Tokyo, Koto-ku
2024-06-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Nagoya, Kashiwa, Ōta, Sapporo, Isehara, Kawasaki, Sagamihara, Yokohama
2024-06-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Nagoya, Kashiwa, Sapporo, Isehara, Kawasaki, Sagamihara, Yokohama, Tsu
2024-04-14
Active, closed
Janssen Research & Development, LLC
Phase 3
774
Fukuoka, Fukutsu, Gifu, Ginowan, Gunma, Hokkaido, Isehara, Kawasaki
2024-01-17
By invitation
Sanofi
Phase 3
90
Isehara, Tsu, Ureshino, Fukuoka
2024-01-03
Recruiting
CellSeed Inc.
Phase 3
96
Ebina, Isehara, Yokohama, Bunkyō-Ku
2023-10-20
Active, closed
Celgene
Phase 3
79
Nagoya, Sapporo, Nishinomiya, Kanazawa, Isehara, Shibuya-ku, Chiba, Fukuoka
2023-10-16
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Narita, Matsuyama, Gifu, Kobe, Isehara, Suita, Shinjuku Ku, tabashi City
2022-12-30
Recruiting
Janssen Research & Development, LLC
Phase 2/3
201
Asahikawa, Bunkyō City, Chiba, Hamamatsu, Isehara, Kobe, Kodaira-shi, Koshigaya
2022-09-23
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsNemtabrutinib·Zilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 2
189
Nagoya, Sapporo, Isehara, Sendai, Sakai, Chuo-ku, Koto, Fukuoka
2022-07-21
Active, closed
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755Moderate Aortic Valve Stenosis
Medtronic Cardiovascular
Not applicable
650
Kanagawa, Isehara, Kawasaki, Osaka
2022-04-27
Active, closed
UCB Biopharma SRL
Phase 3
113
Chiba, Isehara, Kitakyushu-shi, Kodaira, Koriyama-shi, Sendai, Shinjuku-ku, Suita-shi
2022-02-02
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Sapporo, Isehara, Tsu, Hirakata, Bunkyo, Minato, Chūō, Fukuoka
2022-01-14
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Nagoya, Chiba, Ichihara, Fukuoka, Sapporo, Kobe, Nishinomiya, Isehara
2021-12-13
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Fukuoka, Gifu, Higashiibaraki-gun, Isehara, Kamakura-shi, Kashiwa, Koshigaya, Kumamoto
2021-10-14
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Nagoya, Isehara, Suwa, Suita, Shinjuku Ku, Fukushima, Ishikawa, Kyoto
2021-07-27
Active, closed
AstraZeneca
Phase 3
506
Isehara, Kawasaki-shi, Sapporo, Shinagawa-ku, Yokohama
2021-06-22
Active, closed
Novartis Pharmaceuticals
Phase 2
36
Narita, Kurume, Ohtake, Nishinomiya, Kanazawa, Isehara, Yokohama, Sendai
2021-05-25
Active, closed
Incyte Corporation
Phase 3
899
Fukuoka, Gifu, Ibaraki, Isehara, Kagoshima, Nagoya, Narita-shi, Okayama
2021-05-11
Recruiting
Bristol-Myers Squibb
Phase 3
153
Nagoya, Fukuoka, Jonan-Ku, Isehara, Tsu, Shinjuku-ku, tabashi City, Osaka
2021-03-23
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Nagoya, Ogaki-shi, Sapporo, Kobe, Isehara, Nankoku, Sendai, Osaka Sayama-shi
2021-03-09
Active, closed
Novartis Pharmaceuticals
Phase 2
24
Nagoya, Kashiwa, Isehara, Yokohama, Kumamoto, Sendai, Osaka, Suita
2021-01-08
Active, closed
Daiichi Sankyo
Phase 3
1,600
Akashi, Chūōku, Fukuoka, Hiroshima, Isehara, Kagoshima, Kashiwa, Kōtoku
2020-12-04
Active, closed
Incyte Corporation
Phase 2
112
Bunkyō City, Chūō, Hirakata, Isehara, Kobe, Kyoto, Matsumoto-shi, Miyagi
2020-08-03
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Cytarabine·Methotrexate
Takeda
Phase 3
245
Chiba, Kashiwa, Fukushima, Sapporo, Isehara, Okayama
2018-10-04
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Nagoya, Sapporo, Isehara, Suita, Bunkyo Ku, Fukuoka, Osaka
2015-03-05
Rows per page Showing 1–52 of 52
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 November 2026. https://priyalifescience.com/clinical-trials-japan/city/isehara

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,516 studies in total at the last sync on 12 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 52 of those studies with a site in Isehara.

How many clinical trials are recruiting in Isehara?

27 of the 52 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 23 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Isehara), 52 studies
PhaseStudiesRecruitingShare
Phase 3281153.8%
Phase 28315.4%
Phase 4549.6%
Phase 2/3447.7%
Not applicable213.8%
Phase 1213.8%
Phase 1/2223.8%
Observational111.9%

Most active sponsors

Lead sponsors with the most studies (Isehara)
Lead sponsorStudiesRecruiting
Eli Lilly and Company65
Merck Sharp & Dohme LLC65
Novartis Pharmaceuticals60
Janssen Research & Development, LLC42
Sanofi31
AbbVie22
Boehringer Ingelheim21
Bristol-Myers Squibb22
Chugai Pharmaceutical21
Daiichi Sankyo21
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.